Insurance Coverage
60 articles on Insurance Coverage, researched and written by the Shotlee Editorial Team from primary sources.
Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss
Rapid weight loss on GLP-1 medications often leads to skin laxity because the body loses subcutaneous fat faster than collagen and elastin can regenerate. This biological lag creates visible sagging, particularly in areas with high elasticity like the jawline and neck.
6 min read
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound
Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.
7 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Semaglutide Telehealth: From The Access Boom To Regulatory Reckoning
The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for major manufacturers while creating unprecedented demand for weight management solutions. Telehealth platforms initially emerged as a critical access channel, offering convenient prescriptions and more affordable compounded versions during national shortages. Yet by 2025 and 2026, the sector faced a sharp pivot as FDA actions resolved shortages and curtailed large-scale compounding operations.
7 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Ozempic, Wegovy, Mounjaro: Who Benefits When Obesity is Labeled a Disease?
As GLP-1 medications like Ozempic, Wegovy, and Mounjaro gain prominence, the medical community and pharmaceutical giants are increasingly framing obesity as a chronic disease. This article delves into the multifaceted implications of this classification, examining its impact on treatment, policy, and patient perception, while questioning who truly benefits from this shift.
7 min read
Ozempic & Wegovy Online: The Risky Rush to Bypass Doctor Consultations
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution in Weight Loss
A closer look at the groundbreaking GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, and their transformative effects on weight management and overall health.
6 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Beyond the Hype: Navigating GLP-1s for Sustainable Health
As demand for GLP-1 medications soars, healthcare professionals emphasize a balanced, comprehensive approach to weight management and chronic disease treatment, focusing on sustainability and patient well-being.
7 min read
Beyond the Headlines: Unpacking the Real GLP-1 Weight Loss Race
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
8 min read
Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.
7 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.
7 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
7 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
GLP-1 Drugs & Your Knees: New Research on Joint Health
Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.
7 min read
Ozempic and the Shift: Real Data on America's Obesity Rates
New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.
7 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
Beyond the Injection: GLP-1s, Diet, and the Future of Weight Management
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
6 min read
Oral Wegovy Approval: What the EU's Decision Means for Weight Loss
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
7 min read
Why Semaglutide and Tirzepatide Are Redefining Weight Loss Culture
Prescriptions for weight loss drugs have tripled since 2020. Discover the science, social impact, and practical tips for navigating the GLP-1 era safely.
6 min read
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
Ozempic, Wegovy, Mounjaro: Will Weight Loss Drug Costs Skyrocket for You?
The soaring popularity and effectiveness of GLP-1 medications for weight loss are undeniably reshaping healthcare landscapes. But as demand surges, so do the costs, leading to significant implications for both employers and the individuals who rely on these treatments. This article delves into the financial pressures, employer strategies, and what you can expect regarding your co-pays and coverage for drugs like Ozempic, Wegovy, and Mounjaro.
8 min read
Beyond Weight Loss: GLP-1s Show Promise Against Inflammation
Initially celebrated for their weight-loss efficacy, GLP-1 receptor agonists are now revealing a broader therapeutic scope. Emerging research suggests these powerful medications may offer significant benefits in combating inflammation and tissue damage, potentially transforming the management of chronic diseases.
6 min read
GLP-1 Weight Loss Drugs: Rising Costs & What It Means for Your Wallet
The soaring popularity and effectiveness of GLP-1 medications for weight loss are driving up healthcare costs, leading to potential increases in employee co-pays and changes in employer coverage strategies. This article explores the financial implications and what you need to know.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
7 min read
Supreme Court Ruling: Medicare Drug Price Negotiations Move Forward
In a significant victory for healthcare cost containment, the Supreme Court has allowed Medicare to proceed with negotiating drug prices. This decision upholds a key provision of the Inflation Reduction Act and could impact the cost of many prescription medications, including widely used GLP-1 agonists.
6 min read
Beat Cravings: A Surgeon's 6-Step Guide to Lasting Fullness
Tired of constant cravings derailing your health goals? A UK surgeon reveals a simple yet effective 6-step strategy to boost satiety and minimize hunger throughout the day. Learn how to leverage the power of fiber, hydration, and smart eating habits for lasting fullness.
7 min read
Wegovy Pill Price: How to Access GLP-1 Therapy for Less
The revolutionary Wegovy pill offers a needle-free approach to GLP-1 weight loss therapy. Discover its pricing, how it compares to injectables, and how programs are working to make this effective treatment more accessible.
7 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
DIY Weight Loss Injections: The Dangerous Rise of 'Skinny Jabs'
As the cost of popular weight loss medications like Mounjaro and Wegovy climbs, a growing number of individuals are resorting to dangerous, unapproved DIY 'skinny jabs' sourced illegally online. This article delves into the risks, motivations, and the alarming reality of this trend.
7 min read
Navigating Prescription Drug Coupons: Savings or Hidden Costs?
Prescription drug coupons can seem like a straightforward way to save money. However, for individuals with health insurance, these discounts can come with unexpected financial implications. This article delves into the nuances of manufacturer-sponsored coupons, their impact on insurance plans, and how to make informed decisions at the pharmacy counter.
7 min read
CVS 2026 Outlook: Impact on GLP-1 Coverage, Insurance, and Care Access
CVS Health exceeded earnings expectations, but what does this mean for patients using GLP-1 medications like Ozempic or Wegovy? We break down the financial news and its real-world implications for your healthcare coverage.
8 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
Medicaid GLP-1 Coverage Changes: Access to Ozempic and Wegovy
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
8 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
GLP-1 Medications & Weight Loss: What's Behind the Buzz?
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
7 min read
The Risks of Cycling GLP-1s: Why Consistency Matters for Weight Loss
New data shows many patients cycle on and off GLP-1 medications. Discover why this approach may hinder long-term health and why tracking is essential.
3 min read
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.
2 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
8 min read
News Personalities' Before & After Ozempic, GLP-1 Weight Loss Pics
Ozempic and other GLP-1 medications are transforming figures in Hollywood and newsrooms alike, with before and after pics of personalities like Oprah Winfrey and Joy Behar showcasing undeniable weight loss. A 2024 study highlights their history since 1986, exploding in popularity post-Wegovy's 2021 FDA approval for weight loss. Spot the telltale Ozempic neck and hands that give away users.
5 min read
Generic Ozempic Semaglutide Gets Tentative USFDA Approval; OneSource CDMO Par...
A generic version of Ozempic semaglutide has received tentative USFDA approval, marking a key step toward affordable GLP-1 therapy. Orbicular spearheaded product development, partnering with OneSource Specialty Pharma as the CDMO for reliable U.S. market manufacturing. This collaboration promises steady commercial supply from an FDA-approved site.
5 min read
How to Keep Weight Off After Ozempic: Proven Strategies
Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.
6 min read
Safely Buy GLP-1 Drugs Online: Key Facts Amid Ad Surge
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
5 min read
Gut Reset Era 2026: Redefining Weight Loss and Digestive Health
In 2026, the gut reset era is transforming weight loss by linking it inseparably to digestive health and metabolism. No longer isolated goals, bloating, slow metabolism, and weight gain are addressed holistically for lasting results. From microbiome breakthroughs to personalized tech tools, this integrated approach promises better outcomes.
7 min read
Quitting GLP-1s Like Ozempic? Many Plan to Restart Despite Risks
Many patients start GLP-1 medications like Ozempic and Zepbound for obesity but quit within a year, with fewer than one in four remaining on treatment. Shockingly, 74% of those who stop plan to restart, despite experts warning against this cycling approach. This guide explores the data, risks like muscle loss, and what it means for your health.
5 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Wegovy Pill Cost: Get It for $149/Month via WeightWatchers Med+
The new FDA-approved Wegovy pill is now available at just $149 per month for starter doses via WeightWatchers Med+, making GLP-1 weight loss therapy more affordable. This self-pay pricing beats typical injectable costs, but it's limited to 1.5mg and 4mg doses for the first four months. Discover eligibility, comparisons, and how to get started before the offer ends April 15.
5 min read
3 Ways Pharmacists Maximize Your GLP-1 Experience
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are key allies in navigating costs, side effects, and long-term success. Experts like Martin Torres, PharmD, emphasize their role in maximizing benefits while minimizing risks. Here are three essential ways they support your GLP-1 experience.
6 min read
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
Pharmacists' Key Role in Helping Patients Maximize GLP-1 Drugs
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are emerging as crucial allies in ensuring treatment success. According to the American Society of Health-System Pharmacists, these experts help navigate costs, side effects, and lifestyle integration. This guide explores their vital role in maximizing benefits and minimizing risks.
5 min read